8.3.15(3). Hoogfrequent audiometrie
Print Friendly, PDF & Email

8.3.15.1(3). Normaalwaarden

De bepaling van de normaalwaarden is gebaseerd op de uitkomsten van 284 oren (142 proefpersonen) met een onbelaste ooranamnese. De – herhaalde – metingen werden verricht bij patiënten die in aanmerking kwamen voor een ototoxische behandeling, tot aan het moment dat, volgens een objectief criterium de eerste ototoxische schade begon op te treden. Tevens is onderzocht of deze referentiecurven sterk afhankelijk zijn van het geslacht. Alleen in de groep van 50-60 jaar is een verschil gevonden, in het voordeel van de vrouwen, maar voor de groep van 60-70 jaar was dit verschil weer minder. Mogelijk komt dit omdat hierbij slechts 3 mannen (6 oren) betrokken waren. Concluderend kan voorlopig gesteld worden, dat de invloed van het geslacht te verwaarlozen is, in ieder geval tot ongeveer 50 jaar.

Literatuur

  1. Dreschler WA, van der Hulst RJAM, Tange RA, Urbanus NAM. The role of high-frequency audiometry in early detection of ototoxicity. Audiology 1985; 24: 387-395.
  2. Fausti SA, Frey RH, Erickson DA, Rappaport BZ, Cleary EJ, Brummett RE. A system for evaluating auditory function from 8000 to 20000 Hz.  J Acoust Soc Amer 1979;66:1713-1718.
  3. Fausti SA, Larson VD, Noffsinger D, Wilson RH, Phillips DS, Fowler CF. High-frequency audiometric monitoring strategies for early detection of ototoxicity. Ear & Hearing 1994; 15: 232-239.
  4. Fausti SA, Henry JA, Helt WJ, Phillips DS, Frey RH, Noffsinger D, Larson VD, Fowler CG. An individualized, sensitive frequency range for early detection of ototoxicity. Ear & Hearing 1999; 20:497-505.
  5. Spoor A. Presbyacusis values in relation to noise induced hearing loss.Int Audiol 1967; 6: 48-57.
  6. Tange RA, Dreschler WA, van der Hulst RJAM. The importance of high-tone audiometry in monitoring for ototoxicity. Arch Otorhinolaryngol 1985;242:77-81.

Overige literatuur

  1. Aguilar-Markulis NV, Beckley S, Priore R, Mettlin C. Auditory toxicity effects of long-term cis-dichlorodiammineplatinum II therapy in genitourinary cancer patients. J Surg Oncol 1981;16:111-123.
  2. Atherley GRC, Dingwall-Fordyce I. The reliability of repeated auditory threshold determination. British Journal of Industrial Medicine 1963;20:231-235.
  3. Blakley BW, Gupta AK, Myers SF, Schwan S. Risk factors for ototoxicity due to cisplatin. Arch Otolaryngol Head Neck Surg 1994;5:541-546.
  4. Brummett RE. Drug-induced ototoxicity. Drugs 1980;19:412-428.
  5. Dobie RA. Reliability and validity of industrial audiometry: Implications for hearing conservation program design. Laryngoscope 1983;93:906-927.
  6. Fausti SA, Frey RH, Erickson DA, Rappaport BZ, Cleary EJ, Brummett RE. A system for evaluating auditory function from 8000 to 20000 Hz.  J Acoust Soc Amer 1979;66:1713-1718.
  7. Fausti SA, Frey RH, Henry JA, Knutsen JM, Olson DJ. Reliability and validity of high-frequency (8-20 kHz) thresholds obtained on a computer-based audiometer as compared to a documented laboratory system. J Amer Acad  Audiol 1990;1:162-170.
  8. Fausti SA, Frey RH, Rappaport BZ, Erickson DA. An investigation of the effects of Bumetanide on high-frequency (8-20 kHz) hearing in humans. J Audit Res 1979;19: 243-250.
  9. Fausti SA, Henry JA, Schaffer HI, Olson DJ, Frey RH, Bagby GC. High-frequency monitoring for early detection of cisplatin ototoxicity. Arch Otolaryngol-Head and Neck Surgery 1993;119:661-666.
  10. Fausti SA, Henry JA, Schaffer HI, Olson DJ, Frey RH, McDonald WJ. High-frequency audiometric monitoring for early detection of arninoglycoside ototoxicity. J Infectious Diseases 1992;165:1026-1032.
  11. Fausti SA, Olson DJ, Frey RH, Schaffer HI. Managing a multisite research program with microcomputerbased communications.  Computer Users in Speech and Hearing 1991;7:11-21.
  12. Fausti SA, Rappaport BZ, Schechter MA, Frey RH, Ward TT, Brummett RE. Detection of aminoglycoside ototoxicity by high-frequency auditory evaluation: selected case studies. Amer J Otolaryngol 1984;5:177-182.
  13. Fausti SA, Schaffer HI, Olson DJ, Frey RH, Henry, JA. Software for managing multi-site auditory research.  Audiology Today 1993;5:22-25.
  14. Fausti SA, Schechter MA, Rappaport BZ, Frey RH.,Mass RE. Early detection of cisplatin ototoxicity: selected case reports. Cancer 1984;53:224-231.
  15. Feghali JG, Bernstein RS. A new approach to serial monitoring of ultra-high frequency hearing. Laryngoscope 1991;8:825-829.
  16. Forastiere AA, Gennis M, Orringer MB, Agha FP. Cisplatin, vinblastine, and mitoguazone chemotherapy for epidermoid and adenocarcinoma of the esophagus. J Clin Oncol 1987;5:1143-1149.
  17. Helson L, Okonkwo E, Anton L, Cvitcovic E. Cisplatinum ototoxicity. Clinical Toxicology 1978;13:469-478.
  18. Jerger JF. Comparative evaluation of some auditory measures. Journal of Speech and Hearing Research 1962;5:3-17.
  19. Kopelman J, Budnick AS, Sessions RB, Kramer MB, Wong GY. Ototoxicity of high-dose cisplatin by bolus administration in patients with advanced cancers and normal hearing. Laryngoscope 1988;98:858-864.
  20. Meyerhoff WL, Malle GE, Yellin W, Roland PS. Audiologic threshold monitoring of patients receiving ototoxic drugs: Preliminary report. Annals Otol RhinolLaryngol 1989;98:950-954.
  21. Phillips DS, Trune DR, Mitchell C. Solving the “One ear vs. two ears” data analysis dilemma. The Hearing Journal 1990;43:27-32.
  22. Powell SH, Thompson WL, Luthe MA. Oncedaily vs. continuous aminoglycoside dosing: Efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin.  J Infect Diseases 1983; 147:918-932.
  23. Sakamoto M, Kaga K, Kamio T. Extended hifh-frequency ototoxicity induced by first administration cisplatin. Ootolaryngol haed neck Surg 2000;6:828-833.
  24. Shaw GM, Jardine CA, Fridjhon P. A pilot investigation of high-frequency audiometry in obscure auditory dysfunction (OAD patients. Br J Audiol 1996;4:233-237.
  25. Sinks B, Goebel J. Test-retest reliability of ultra-high frequency thresholds at bedside with sensorineural hearing impaired listeners.  In Lim DJ (ed.) Abstracts of the Sixteenth Midwinter Research Meeting: Association for Research in Otolaryngology. Des Moines, IA: Association for Research in Otolaryngology 1993:5.
  26. Skinner R, Pearson ADJ, Amineddine HA., Mathias DB, Craft AW. Ototoxicity of cisplatinum in children and adolescents.  British J Cancer 1990;61:927-931.
  27. Tablan OC, Reyes MP, Rintelmann WF, Lerner AM. Renal and auditory toxicity of high-dose, prolonged therapy with gentamicin and tobramycin in pseudomonas endocarditis.  J Infect Diseases 1984;149:257-263.
  28. Thompson PL, Northern JL. Audiometric monitoring of patients treated with ototoxic drugs.  In: Lerner SA, Matz GJ, Hawkins JE-Jr (eds) Aminoglycoside ototoxicity. Boston: Little, Brown and Company 1981;23:7-245).
  29. Valente ML, Gulledge-Potts M, Valente M, French-St.George J, Goebel J. High-frequency thresholds: sound suite versus hospital room. J Am Acad Audiol 1992;3:287-294.

Auteur

Dreschler, van der Hulst

Revisie

2007